Three-year results of denosumab treatment for osteoporosis in women with rheumatoid arthritis and primary osteoporosis: A clinical observational study.

Abstract

INTRODUCTION:

This study investigated the results of 3 years of denosumab treatment for osteoporosis in women with rheumatoid arthritis (RA) and primary osteoporosis (PO).

MATERIALS AND METHODS:

This study enrolled 112 women with RA (RA group) and 104 women with a PO group who received 60 mg denosumab for 3 years. Bone mineral densitiy (BMD) of the lumbar spine, total hip and femoral neck as well as levels of bone turnover markers [N-terminal propeptide of type I procollagen (P1NP) and tartrate-resistant acid phosphatase-5b (TRACP-5b)] were measured at years 1, 2, and 3.

RESULTS:

The percent changes (Δ) in BMD values at years 1, 2, and 3 were as follows: RA group: 6.7 ± 6.2%, 8.9 ± 6.5%, and 9.8 ± 8.2% and PO group: 6.0 ± 4.8%, 8.9 ± 7.5%, and 12.6 ± 8.7% for the lumbar spine; RA group: 4.5 ± 4.6%, 5.2 ± 5.1%, and 6.8 ± 5.9% and PO group: 3.8 ± 4.5%, 4.6 ± 7.4%, and 6.8 ± 4.6% for the total hip; and RA group: 2.7 ± 5.1%, 4.1 ± 6.8%, and 4.3 ± 6.7% and PO group: 3.6 ± 8.0%, 4.5 ± 10.9%, and 5.7 ± 10.5% for the femoral neck, respectively. The ΔBMD for the lumbar spine, total hip, and femoral neck as well as ΔP1NP and ΔTRACP-5b did not differ significantly between the two groups at any time points.

CONCLUSION:

Denosumab treatment for osteoporosis had a similar efficacy over 3 years among women with RA and PO. A better understanding of denosumab treatment for this patient population is important in clinical practice.

• Authors: Takeshi Mochizuki, Koichiro Yano, Katsunori Ikari, Ryo Hiroshima, Yuki Nasu, Ken Okazaki
• Journal: Modern rheumatology (Mod Rheumatol) Vol. 31 Issue 3 Pg. 600-606 (May 2021) ISSN: 1439-7609 [Electronic] England
• PMID: 32815449 (Publication Type: Journal Article, Observational Study)

Chemical References

• Bone Density Conservation Agents
• Denosumab

Topics

• Aged
• Arthritis, Rheumatoid (complications)
• Bone Density
• Bone Density Conservation Agents (administration & dosage, therapeutic use)
• Denosumab (administration & dosage, therapeutic use)
• Female
• Humans
• Lumbar Vertebrae (pathology)
• Middle Aged
• Osteoporosis (complications, drug therapy)